---
title: "In \"The Big Bank,\" Citigroup: INNOVENT BIO's collaboration with Takeda Pharmaceutical is positive for advancing product development, target price raised to 120.1 yuan"
description: "Citi released a research report indicating that INNOVENT BIO has reached a global strategic cooperation with Takeda Pharmaceutical to jointly develop the next-generation IO cornerstone therapy IBI363,"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262340325.md"
published_at: "2025-10-23T03:03:34.000Z"
---

# In "The Big Bank," Citigroup: INNOVENT BIO's collaboration with Takeda Pharmaceutical is positive for advancing product development, target price raised to 120.1 yuan

> Citi released a research report indicating that INNOVENT BIO has reached a global strategic cooperation with Takeda Pharmaceutical to jointly develop the next-generation IO cornerstone therapy IBI363, and has authorized the collaboration for IBI343 and IBI3001. This cooperation positively impacts INNOVENT's global layout and product development progress, particularly advancing the development of IBI363. Citi has raised its sales and net profit forecasts for INNOVENT BIO for the fiscal year 2026 by 48.5% and 172%, respectively, increasing the target price from 111.4 yuan to 120.1 yuan, while maintaining a "outperform" rating

Citi published a research report stating that INNOVENT BIO (01801.HK) and Takeda Pharmaceutical (4502.JP) announced a global strategic collaboration. The two parties will jointly develop the next-generation IO cornerstone therapy IBI363 globally and have reached a licensing agreement for the projects IBI343 and IBI3001. Citi believes this collaboration is positive for INNOVENT's global layout and product development progress, especially in promoting the development of the core project IBI363.

IBI363 was approved by the U.S. FDA in August this year to initiate a Phase III clinical trial for the treatment of squamous non-small cell lung cancer. Citi believes that the plan for both parties to commercialize IBI363 in the U.S. will help unlock market value, as Takeda has a strong U.S. commercial franchise and is experienced in this market.

Taking into account the impact of this collaboration, Citi has raised its sales and net profit forecasts for INNOVENT BIO for the fiscal year 2026 by 48.5% and 172%, respectively, and raised the net profit forecast for fiscal year 2027 by 1.5%. The target price has been raised from HKD 111.4 to HKD 120.1, maintaining a "Outperform" rating

### Related Stocks

- [01801.HK - INNOVENT BIO](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 野村將信達生物的目標價從 105.08 港元調整至 114.64 港元，並維持買入評級 | 野村將信達生物的目標價從 105.08 港元調整至 114.64 港元，維持 “買入” 評級 | [Link](https://longbridge.com/en/news/275882948.md) |
| 信達生物的第四季度收入增長了 60% | 信達生物第四季度收入激增 60% | [Link](https://longbridge.com/en/news/274820825.md) |
| 黃仁勳：英偉達將發布幾款前所未有的全新晶片 | 英偉達執行長黃仁勳接受外媒訪問時稱，該企已經為下月的年度 AI 盛會 GTC 2026 準備了幾款前所未有的全新晶片。 他補充，「由於所有技術都已達到極限，所以沒有什麼是容易的」。但強調因擁有一支由英偉達和 SK 海力士的內存工程師組成的團 | [Link](https://longbridge.com/en/news/276419680.md) |
| 黃仁勳稱將發佈「令世界驚訝」新晶片「所有技術都已經逼近極限」 | 英偉達執行長黃仁勳在接受《韓國經濟日報》採訪時透露，將於 2026 年 3 月 16 日在聖何塞的 GTC 大會上發布一款「令世界驚訝」的新晶片。他表示，所有技術都已逼近極限，但有信心通過團隊合作克服挑戰。新晶片可能基於 Rubin 架構或 | [Link](https://longbridge.com/en/news/276297645.md) |
| Meta 擬部署「數百萬夥」Nvidia 晶片 進一步加強合作關係 | Meta 計劃在未來幾年內部署數百萬顆 Nvidia 的 Blackwell 與 Rubin GPU，進一步加強與 Nvidia 的合作關係。此舉將使 Meta 更多地使用 Nvidia 的 AI 處理器和網絡設備，預計將為 Nvidia  | [Link](https://longbridge.com/en/news/276193053.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.